Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma.
Maria VieitoMatteo SimonelliFilip de VosVictor MorenoMarjolein GeurtsElena LorenziMarina MacchiniMartin J Van Den BentGianluca Del ConteMaja de JongeMaria Cruz Martín-SoberónBarbara AmorosoTania Sanchez-PerezMarlene ZuraekBishoy HannaIda AronchikEllen FilvaroffHenry ChangCristina MendezMarina Arias ParroXin WeiZariana NikolovaJuan Manuel SepulvedaPublished in: Neuro-oncology advances (2022)
Trotabresib combined with TMZ in the adjuvant setting and with TMZ+RT in the concomitant setting was safe and well tolerated in patients with ndGBM, with encouraging treatment durations. Trotabresib 30 mg was established as the RP2D in both settings.